Impact of Hypoglycemia on Hospitalized Patients With Hepatocellular Carcinoma.

Autor:	Iqbal R; Medicine, The Brooklyn Hospital Center, Brooklyn, USA., Solipuram D; Internal Medicine, Nassau University Medical Center, East Meadow, USA., Mohammed YN; Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, USA., Bajwa AT; Oncology, Brooklyn Cancer Care, Brooklyn, USA., Irfan A; Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA., Jafar A; Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK., Rehman Z; Internal Medicine, Hayatabad Medical Complex, Peshawar, PAK., Islam ZU; Internal Medicine, Nishtar Medical University, Multan, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jul 16; Vol. 16 (7), pp. e64673. Date of Electronic Publication: 2024 Jul 16 (Print Publication: 2024).
DOI:	10.7759/cureus.64673
Abstrakt:	Aims Hepatocellular carcinoma (HCC) is one of the common liver malignancies that presents a challenge to global healthcare. The impact and outcomes of hypoglycemia in HCC have not been studied in detail before. This study aimed to investigate the outcomes and prognosis associated with hypoglycemia in patients diagnosed with HCC, utilizing a large-scale database approach. Methods Using the Nationwide Inpatient Sample (NIS) database from 2017 to 2020, we conducted a comprehensive retrospective analysis to examine the incidence, risk factors, and clinical implications of hypoglycemia on HCC patients. The patients were divided into two groups: those with hypoglycemia and those without hypoglycemia. Univariate and multivariate logistic regression were used to conduct the analysis. STATA® version 17.0 software (StataCorp LLC, College Station, TX) was used for this purpose. Results Out of a total of 343,895 patients with HCC, the prevalence of hypoglycemia was present in 1.5% of this patient population. We found that hypoglycemia was common in the male population (68%). Compared with patients without hypoglycemia, patients who had hypoglycemia with HCC had higher mortality (42%, p-value < 0.05) and higher risks of secondary outcomes such as hepatic failure, spontaneous bacterial peritonitis (SBP), ascites, and portal vein thrombosis compared to patients who did not have hypoglycemia. The multivariate-adjusted odds ratio for hepatic failure was 2.7 (2.3-3.1), for SBP was 2.9 (1.8-3.0), for ascites was 1.6 (1.4-1.9), and for portal vein thrombosis was 1.2 (0.9-1.4). Conclusion In conclusion, hypoglycemia in HCC is associated with increased mortality and worse outcomes. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Iqbal et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu